Rosen Law Firm Investigates Disc Medicine, Inc. After FDA CRL
News related to:Disc Medicine, Inc · 1 min read
Rosen Law Firm, a global investor rights law firm, has initiated an investigation into potential securities claims for shareholders of Disc Medicine, Inc. (NASDAQ: IRON), following allegations of misleading business information.
On February 13, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Disc Medicine regarding its bitopertin program. The FDA stated that uncertainties in the company’s new drug application (NDA) necessitated additional evidence, which led to a significant drop in the company’s stock price. The share price fell 22% on the day of the CRL announcement, reflecting investors' concerns about the potential impact on the company’s future.
According to the press release, the Rosen Law Firm has a track record of success in leading securities class actions and has achieved significant settlements for investors. The firm represents investors globally and has been recognized for its accomplishments in this field.
If you purchased Disc Medicine securities, you may be entitled to compensation without incurring any out-of-pocket legal fees. The Rosen Law Firm encourages shareholders to seek legal advice to understand their rights and potential remedies.